Yongli Gu

Yongli Gu is a scientist II, bioanalysis at Verve Therapeutics, with expertise in bioanalytical assay development for preclinical studies, molecular biology, biochemistry, and cell biology. Prior to joining Verve, Yongli worked on anti-drug antibody assays, protein binding assays, and assay development at Alnylam Pharmaceuticals. Prior to Alnylam, Yongli worked on assay development and compound screening for Alzheimer’s disease at Brigham and Women’s Hospital. Yongli received her M.S. in Biochemistry from Kansas State University.